# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and maintains $23 p...
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating a...
Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and raises the price t...
HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...
Oppenheimer analyst Matthew Biegler maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price targ...
Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and announces $15 pric...